Facebook



Twitter

Therapy

In recent years numerous life-saving treatment options have been developed for the therapy of breast cancer. Today there is a wide selection of treatments available to fight each individual breast cancer type. For a personalized treatment recommendation, different approaches are selected and combined based on a sound diagnosis.

Clinical parameters guide the oncologist in assessing the suitable intervention e.g.:
• Surgery
• Sentinel lymph node biopsy
• Radiation therapy

In order to optimize the outcome the treatment regimen is typically complemented by a systemic therapy like:
• Chemotherapy
• Anti-hormone therapy
• Targeted therapy

BCS (Breast Conserving Surgery)
based on http://onkopedia-guidelines.info

Subtype Systemic Therapy Benefits of MammaTyper®
Luminal A-like Endocrine therapy Based on accurate measurement MammaTyper® supports differentiation of low risk
Luminal A-like from high risk Luminal B-like by precise and reproducible MKI67 determination
Luminal B-like (HER2 negative) Endocrine therapy
+
Cytotoxics
Accurate determination of hormone receptor > endocrine responder or non –responder
Precise differentiation of low risk Luminal A-like from high risk Luminal B-like by accurate and reproducible MKI67 determination by MammaTyper®
Luminal B-like (HER2 positive) Endocrine therapy
+
Cytotoxics
+
Anti-HER2
Accurate determination of hormone receptor expression by MammaTyper® > endocrine responder or non –responder

Accurate determination of ERBB2 expression by MammaTyper®

HER2 positive (non-luminal) Anti-HER2 Accurate determination of ERBB2 expression by MammaTyper®
Triple negative (ductal) Cytotoxics Accurate determination of ERBB2, ESR1, PGR expression negativity by MammaTyper®

Based on the identified molecular subtype the 13th St Gallen International Breast Cancer Conference (2013) Expert Panel has established clear recommendations for the choice of most effective systemic treatments.